Cue Biopharma Inc [CUE] stock is trading at $185800.0, up 1055258%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CUE shares have gain 10.22% over the last week, with a monthly amount glided 4.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cue Biopharma Inc [NASDAQ: CUE] stock has seen the most recent analyst activity on March 13, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $6. On November 21, 2022, Piper Sandler initiated with a Overweight rating and assigned a price target of $7 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $20 on January 13, 2022. Craig Hallum initiated its recommendation with a Buy and recommended $28 as its price target on January 03, 2022. Berenberg started tracking with a Buy rating for this stock on November 24, 2020, and assigned it a price target of $30. In a note dated April 09, 2020, Stifel initiated an Buy rating and provided a target price of $21 on this stock.
Cue Biopharma Inc [CUE] stock has fluctuated between $0.45 and $1.99 over the past year. Currently, Wall Street analysts expect the stock to reach $4.33 within the next 12 months. Cue Biopharma Inc [NASDAQ: CUE] shares were valued at $185800.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average CUE price forecast.
Analyzing the CUE fundamentals
Cue Biopharma Inc [NASDAQ:CUE] reported sales of 7.99M for the trailing twelve months, which represents a drop of -75.48%. Gross Profit Margin for this corporation currently stands at -0.25% with Operating Profit Margin at -5.15%, Pretax Profit Margin comes in at -5.08%, and Net Profit Margin reading is -5.08%. To continue investigating profitability, this company’s Return on Assets is posted at -1.82, Equity is -2.28 and Total Capital is -6.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Cue Biopharma Inc’s Current Ratio is 1.03. Further, the Quick Ratio stands at 1.03, while the Cash Ratio is 0.85. Considering the valuation of this stock, the price to sales ratio is 6.61, the price to book ratio is 6.58.
Transactions by insiders
Recent insider trading involved PASSERI DANIEL R, CHIEF EXECUTIVE OFFICER, that happened on Dec 16 ’24 when 30000.0 shares were purchased.
